DK175216B1 - Dihydropyridinformulering med forlænget frigivelse og fremstilling heraf - Google Patents

Dihydropyridinformulering med forlænget frigivelse og fremstilling heraf Download PDF

Info

Publication number
DK175216B1
DK175216B1 DK198700477A DK47787A DK175216B1 DK 175216 B1 DK175216 B1 DK 175216B1 DK 198700477 A DK198700477 A DK 198700477A DK 47787 A DK47787 A DK 47787A DK 175216 B1 DK175216 B1 DK 175216B1
Authority
DK
Denmark
Prior art keywords
calcium channel
alkyl
acting
pharmaceutical composition
long
Prior art date
Application number
DK198700477A
Other languages
Danish (da)
English (en)
Other versions
DK47787A (da
DK47787D0 (da
Inventor
Michael John Dey
Calum Brechin Mac Farlane
Alistair Brereton Selkirk
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of DK47787D0 publication Critical patent/DK47787D0/da
Publication of DK47787A publication Critical patent/DK47787A/da
Application granted granted Critical
Publication of DK175216B1 publication Critical patent/DK175216B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198700477A 1986-01-30 1987-01-29 Dihydropyridinformulering med forlænget frigivelse og fremstilling heraf DK175216B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US82389686 1986-01-30
US94087886A 1986-12-10 1986-12-10
US94087886 1986-12-10

Publications (3)

Publication Number Publication Date
DK47787D0 DK47787D0 (da) 1987-01-29
DK47787A DK47787A (da) 1987-07-31
DK175216B1 true DK175216B1 (da) 2004-07-12

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198700477A DK175216B1 (da) 1986-01-30 1987-01-29 Dihydropyridinformulering med forlænget frigivelse og fremstilling heraf

Country Status (18)

Country Link
EP (1) EP0231026B1 (sv)
JP (1) JP2524990B2 (sv)
KR (1) KR900005009B1 (sv)
AU (1) AU604672B2 (sv)
CA (1) CA1285227C (sv)
DE (1) DE3782439T2 (sv)
DK (1) DK175216B1 (sv)
ES (1) ES2052500T3 (sv)
FI (1) FI88872C (sv)
GR (1) GR3006148T3 (sv)
HU (1) HU196709B (sv)
IE (1) IE61879B1 (sv)
IL (2) IL81419A0 (sv)
IT (1) IT1206876B (sv)
NO (1) NO174325C (sv)
NZ (1) NZ219090A (sv)
PH (1) PH26366A (sv)
PT (1) PT84213B (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB2209669B (en) * 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
CA2126441C (en) * 1991-12-30 1999-12-21 David F. Erkoboni Microcrystalline cellulose spheronization composition
EP0557064B1 (en) * 1992-02-20 1997-06-11 Euroceltique S.A. Modified release formulation
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
TW474824B (en) * 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP1970052A2 (en) 1999-02-09 2008-09-17 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
HUT42950A (en) 1987-09-28
NZ219090A (en) 1990-04-26
ES2052500T3 (es) 1994-07-16
KR900005009B1 (ko) 1990-07-16
EP0231026A1 (en) 1987-08-05
HU196709B (en) 1989-01-30
DE3782439T2 (de) 1993-05-19
IL81419A (en) 1991-07-18
IT8767057A0 (it) 1987-01-29
AU604672B2 (en) 1991-01-03
KR870007121A (ko) 1987-08-17
CA1285227C (en) 1991-06-25
NO870368L (no) 1987-07-31
FI870380A (fi) 1987-07-31
NO870368D0 (no) 1987-01-29
IE870229L (en) 1987-07-30
NO174325B (no) 1994-01-10
FI870380A0 (fi) 1987-01-29
DK47787A (da) 1987-07-31
AU6810287A (en) 1987-08-06
FI88872B (fi) 1993-04-15
GR3006148T3 (sv) 1993-06-21
FI88872C (sv) 1993-07-26
DE3782439D1 (de) 1992-12-10
JPS62252732A (ja) 1987-11-04
EP0231026B1 (en) 1992-11-04
NO174325C (no) 1994-04-20
IL81419A0 (en) 1987-08-31
DK47787D0 (da) 1987-01-29
IE61879B1 (en) 1994-11-30
PT84213B (pt) 1989-03-30
PT84213A (en) 1987-02-01
IT1206876B (it) 1989-05-11
PH26366A (en) 1992-06-01
JP2524990B2 (ja) 1996-08-14

Similar Documents

Publication Publication Date Title
US4940556A (en) Method of preparing long acting formulation
US5198226A (en) Long acting nicardipine hydrochloride formulation
DK175216B1 (da) Dihydropyridinformulering med forlænget frigivelse og fremstilling heraf
US5209933A (en) Long acting calcium channel blocker composition
JP2637981B2 (ja) 吸収制御薬剤組成物
FI93422C (sv) Förfarande för framställning av ett peroralt preparat som innehåller en syraostabil benzimidazolderivat
CA2343376C (en) Sustained release ranolazine formulations
CA2791171C (en) Apixaban formulations
US4942040A (en) Pharmaceutical preparation and a process for its preparation
PT1689370E (pt) Método para a preparação de uma composição farmacêutica sólida para administração oral
JP2009532462A (ja) 調節放出クロピドグレル製剤
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
WO1989002738A1 (en) Sustained-release nifedipine formulation
CA2374039C (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
PT1441700E (pt) Método para a preparação de uma composição compreendendo ácido 5-aminosalicílico para uso em tratamento de colites ulcerosas ou da doença de crohn
BR112014020184B1 (pt) Preparação farmacêutica que contém anlodipina e ra-mipril
BR112013003158B1 (pt) composições farmacêuticas de antagonistas do receptor glutamato metabotrópico 5 (mglu5)
BR112019015107A2 (pt) Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel
JPWO2002060448A1 (ja) 医薬組成物
IE990406A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
JPH11171769A (ja) ３−イソブチリル−２−イソプロピルピラゾロ〔１，５−ａ〕ピリジンの徐放性製剤及びその製法
AU2017228681B2 (en) Apixaban formulations
JPH10167966A (ja) 経口持続性製剤
JP2001513100A (ja) デクスフェンフルラミンのプログラムされた放出のための製薬学的組成物
IE60929B1 (en) Controlled absorption diltiazem formulation

Legal Events

Date Code Title Description
PUP Patent expired